After years of being cleared on the European market, Nyxoah’s neuromodulation therapy for obstructive sleep apnea has now ...

The FDA has approved the Genio system for the treatment of patients with moderate to severe obstructive sleep apnea.

The FDA has approved the Genio® system for treating patients with moderate to severe obstructive sleep apnea (OSA) with an ...

Nyxoah SA (NASDAQ:NYXH) saw its stock rise 9.4% after the FDA granted approval for its Genio system designed to treat ...

Nyxoah is in the midst of a lawsuit brought on by Inspire Medical Systems alleging infringement of several patents related to its recently-cleared offering, Genio.

Genio is a different approach to hypoglossal nerve stimulation (HGNS) for the treatment of OSA. Genio’s unique design ...

Nyxoah announced today that it received FDA approval for its Genio neuromodulation device for treating sleep apnea.

Preliminary, Unaudited Second Quarter 2025 Financial Results and Business Updates Announced on August 8, 2025, that the U.S.

Investing.com -- Nyxoah SA (BR:NYXH) (NASDAQ: NYXH) stock jumped 9.4% following FDA approval of its Genio system for treating moderate to severe obstructive sleep apnea (OSA).

NASHVILLE, Tenn. (Ivanhoe Newswire) – Obstructive sleep apnea is a medical condition that causes the upper airway to collapse during sleep – in fact, 40,000 die from it each year. Breathing ...

NASHVILLE, Tenn. (Ivanhoe Newswire) - Obstructive sleep apnea is a medical condition that causes the upper airway to collapse during sleep. In fact, 40,000 people die from it each year.